Table 2 Changes in REVEAL risk score at ≥6-month time point: overall and by time since diagnosis and PAH therapy
Baseline score, mean (SD) | ≥6-month score, mean (SD) | Mean change (95% CI) | p-value | |
|---|---|---|---|---|
Total (n = 57) | 8.7 (2.4) | 7.2 (2.4) | −1.4 (−2.0, −0.9) | < 0.0001 |
Macitentan monotherapy (n = 25) | 7.8 (2.2) | 6.5 (2.4) | −1.2 (− 2.0, − 0.5) | 0.0050 |
Macitentan + PDE5 inhibitor (n = 25) | 9.5 (2.3) | 7.9 (2.5) | −1.6 (−2.7, − 0.5) | 0.0070 |
Macitentan + prostacyclin / Macitentan + PDE5 inhibitor + prostacyclin (n = 7) | 8.9 (2.3) | 7.4 (2.2) | −1.4 (−2.7, −0.1) | 0.0308 |
Incident (n = 23) | 8.9 (2.7) | 7.0 (2.3) | −1.8 (−3.0, −0.7) | 0.0040 |
Macitentan monotherapy (n = 15) | 7.9 (2.2) | 6.6 (2.2) | −1.3 (−2.5, − 0.2) | 0.0300 |
Macitentan + PDE5 inhibitor (n = 8) | 10.6 (2.7) | 7.9 (2.4) | −2.8 (−5.8, − 0.3) | 0.0650 |
Prevalent (n = 34) | 8.5 (2.2) | 7.4 (2.6) | −1.2 (− 1.8, −0.5) | 0.0010 |
Macitentan monotherapy (n = 10) | 7.5 (2.3) | 6.4 (2.8) | −1.1 (−2.2, 0.04) | 0.0707 |
Macitentan + PDE5 inhibitor (n = 17) | 9.0 (2.0) | 8.0 (2.6) | −1.1 (−2.1, −0.04) | 0.0516 |
Macitentan + prostacyclin / Macitentan + PDE5 inhibitor + prostacyclin (n = 7) | 8.9 (2.3) | 7.4 (2.2) | −1.4 (−2.7, −0.1) | 0.0308 |